Thyroid Cancer Staging: Historical Evolution and Analysis From Macrocarcinoma to Microcarcinoma / Carlos Esteban Builes Montaño ; Londoño Bustamante, Andrés Felipe ; Julio Andrés Valencia Ferro ; Duque, Carlos S. ; Tobón Ospina, Catalina ; Alejandro Vélez Hoyos ; Sánchez, Juan G. ; Agudelo, Miguel ; Dueñas, Juan P. ; Palacio, Maria F. ; Sierra, Natalia  

Público ISBD Título : Thyroid Cancer Staging: Historical Evolution and Analysis From Macrocarcinoma to Microcarcinoma Tipo de documento : documento electrónico Autores : Carlos Esteban Builes Montaño, Autor ; Londoño Bustamante, Andrés Felipe, Autor ; Julio Andrés Valencia Ferro, Autor ; Duque, Carlos S., Autor ; Tobón Ospina, Catalina, Autor ; Alejandro Vélez Hoyos, Autor ; Sánchez, Juan G., Autor ; Agudelo, Miguel, Autor ; Dueñas, Juan P., Autor ; Palacio, Maria F., Autor ; Sierra, Natalia, Autor Fecha de publicación : 2025 Títulos uniformes : Cureus Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave : classification  prognosis  risk  staging  surgery  thyroid cancer  tnm Resumen : The classification of thyroid cancer diagnosis and treatment has evolved dramatically since the Union for International Cancer Control (UICC) published the first staging system in 1968. A careful review of the eight published editions of well-differentiated thyroid cancer (WDTC) staging by the UICC and the American Joint Committee on Cancer (AJCC) was performed. Each edition was analyzed to clearly understand which development published and accepted by specialists treating thyroid cancer justified considering a new updated edition. This study presents a comprehensive review of the remarkable evolution of thyroid cancer staging, highlighting the various changes in several areas throughout the years and editions. There were surprising changes within the eight publications: the tumor size was progressively reduced from 4 cm in the first AJCC volume to less than 1 cm in the seventh and eighth UICC and AJCC editions, classifying these small, WDTCs known up to now as “microcarcinomas.” Extrathyroidal extension was accepted after the third edition; this description certainly plays a key role in today’s decisions to manage this tumor as a prognostic factor. The age specification of 45 years prevailed for seven consecutive publications until it was raised to 55 years in the eighth thyroid cancer staging system. Without a doubt, this iconic change allowed physicians around the world to give their 45-year-old thyroid cancer patients a more encouraging panorama of the disease with the new classification. Over the course of nearly 57 years, thyroid cancer staging has undergone remarkable changes, reaching a level of certainty that not only provides recommendations for safer treatments with less surgery and adjunctive measures but also improves survival rates and patient safety. Mención de responsabilidad : Carlos S. Duque , Carlos E. Builes-Montaño , Catalina Tobón-Ospina , Alejandro Velez Hoyos , Juan G. Sánchez , Andres F. Londoño , Miguel Agudelo , Julio A. Valencia , Juan P. Dueñas , Maria F. Palacio , Natalia Sierra Referencia : Cureus 17(4): e81972. DOI (Digital Object Identifier) : 10.7759/cureus.81972 Derechos de uso : CC BY-NC-ND En línea : https://www.cureus.com/articles/350600-thyroid-cancer-staging-historical-evoluti [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Thyroid Cancer Staging: Historical Evolution and Analysis From Macrocarcinoma to Microcarcinoma [documento electrónico] / Carlos Esteban Builes Montaño, Autor ; Londoño Bustamante, Andrés Felipe, Autor ; Julio Andrés Valencia Ferro, Autor ; Duque, Carlos S., Autor ; Tobón Ospina, Catalina, Autor ; Alejandro Vélez Hoyos, Autor ; Sánchez, Juan G., Autor ; Agudelo, Miguel, Autor ; Dueñas, Juan P., Autor ; Palacio, Maria F., Autor ; Sierra, Natalia, Autor . - 2025. Obra : Cureus Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave : classification  prognosis  risk  staging  surgery  thyroid cancer  tnm Resumen : The classification of thyroid cancer diagnosis and treatment has evolved dramatically since the Union for International Cancer Control (UICC) published the first staging system in 1968. A careful review of the eight published editions of well-differentiated thyroid cancer (WDTC) staging by the UICC and the American Joint Committee on Cancer (AJCC) was performed. Each edition was analyzed to clearly understand which development published and accepted by specialists treating thyroid cancer justified considering a new updated edition. This study presents a comprehensive review of the remarkable evolution of thyroid cancer staging, highlighting the various changes in several areas throughout the years and editions. There were surprising changes within the eight publications: the tumor size was progressively reduced from 4 cm in the first AJCC volume to less than 1 cm in the seventh and eighth UICC and AJCC editions, classifying these small, WDTCs known up to now as “microcarcinomas.” Extrathyroidal extension was accepted after the third edition; this description certainly plays a key role in today’s decisions to manage this tumor as a prognostic factor. The age specification of 45 years prevailed for seven consecutive publications until it was raised to 55 years in the eighth thyroid cancer staging system. Without a doubt, this iconic change allowed physicians around the world to give their 45-year-old thyroid cancer patients a more encouraging panorama of the disease with the new classification. Over the course of nearly 57 years, thyroid cancer staging has undergone remarkable changes, reaching a level of certainty that not only provides recommendations for safer treatments with less surgery and adjunctive measures but also improves survival rates and patient safety. Mención de responsabilidad : Carlos S. Duque , Carlos E. Builes-Montaño , Catalina Tobón-Ospina , Alejandro Velez Hoyos , Juan G. Sánchez , Andres F. Londoño , Miguel Agudelo , Julio A. Valencia , Juan P. Dueñas , Maria F. Palacio , Natalia Sierra Referencia : Cureus 17(4): e81972. DOI (Digital Object Identifier) : 10.7759/cureus.81972 Derechos de uso : CC BY-NC-ND En línea : https://www.cureus.com/articles/350600-thyroid-cancer-staging-historical-evoluti [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD002371	AC-2025-054	Archivo digital	Producción Científica	Artículos científicos	Disponible

Early stimulated thyroglobulin after thyroidectomy for thyroid cancer predicts pre-radioiodine therapy thyroglobulin values / Julio Andrés Valencia Ferro  

Público ISBD Título : Early stimulated thyroglobulin after thyroidectomy for thyroid cancer predicts pre-radioiodine therapy thyroglobulin values Tipo de documento : documento electrónico Autores : Julio Andrés Valencia Ferro, Fecha de publicación : 2022 Títulos uniformes : Minerva Endocrinology Idioma : Inglés (eng) Palabras clave : Thyroid neoplasms  Thyroglobulin  Thyroidectomy Resumen : Introduction: Follow-up of patients who undergo a total thyroidectomy is performed with thyroglobulin (Tg), and anti-thyroglobulin antibodies (AbTg). The objective of RAI adjuvant therapy is to negativize Tg to undetectable levels to ease the follow-up. The objective of this study was to evaluate the correlation of serum Tg values measured 2 weeks after surgery with the Tg value prior to RAI adjuvant therapy in order to define its utility as a reliable predictor of pre-therapy Tg and as a potential predictor to avoid RAI adjuvant therapy. Methods: Retrospective analysis of a cohort recruited prospectively. Adult patients with thyroid carcinoma who underwent total thyroidectomy and classified as intermediate or high risk by ATA guidelines. All patients were left without levothyroxine support after surgery and for at least two weeks. We measured biochemical markers two-four weeks after thyroidectomy and before and after RAI. Results: We included 75 patients. Thirty-three (44.0%) patients were classified as ATA high risk. In the post-RAI scan, only 1 (1.3%) showed distant metastases. The comparison between early post-operative and pre-therapy Tg values showed that Tg decreased or remained stable at postoperative levels in 75 patients (100%). Conclusions: Postoperative Tg measurements are a reliable marker of pretherapy Tg levels in patients with intermediate- and high-risk thyroid carcinoma who are candidates for RAI adjuvant therapy. These results need correlation with outcomes and response to therapy in high-risk patients. Mención de responsabilidad : Julio Valencia, Jorge Jiménez, Alvaro Sanabria Referencia : Minerva Endocrinol (Torino). 2022 Jul 13. DOI (Digital Object Identifier) : 10.23736/S2724-6507.22.03813-1 PMID : 35822431 En línea : https://www.minervamedica.it/en/journals/minerva-endocrinology/article.php?cod=R [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Early stimulated thyroglobulin after thyroidectomy for thyroid cancer predicts pre-radioiodine therapy thyroglobulin values [documento electrónico] / Julio Andrés Valencia Ferro,  . - 2022. Obra : Minerva Endocrinology Idioma : Inglés (eng) Palabras clave : Thyroid neoplasms  Thyroglobulin  Thyroidectomy Resumen : Introduction: Follow-up of patients who undergo a total thyroidectomy is performed with thyroglobulin (Tg), and anti-thyroglobulin antibodies (AbTg). The objective of RAI adjuvant therapy is to negativize Tg to undetectable levels to ease the follow-up. The objective of this study was to evaluate the correlation of serum Tg values measured 2 weeks after surgery with the Tg value prior to RAI adjuvant therapy in order to define its utility as a reliable predictor of pre-therapy Tg and as a potential predictor to avoid RAI adjuvant therapy. Methods: Retrospective analysis of a cohort recruited prospectively. Adult patients with thyroid carcinoma who underwent total thyroidectomy and classified as intermediate or high risk by ATA guidelines. All patients were left without levothyroxine support after surgery and for at least two weeks. We measured biochemical markers two-four weeks after thyroidectomy and before and after RAI. Results: We included 75 patients. Thirty-three (44.0%) patients were classified as ATA high risk. In the post-RAI scan, only 1 (1.3%) showed distant metastases. The comparison between early post-operative and pre-therapy Tg values showed that Tg decreased or remained stable at postoperative levels in 75 patients (100%). Conclusions: Postoperative Tg measurements are a reliable marker of pretherapy Tg levels in patients with intermediate- and high-risk thyroid carcinoma who are candidates for RAI adjuvant therapy. These results need correlation with outcomes and response to therapy in high-risk patients. Mención de responsabilidad : Julio Valencia, Jorge Jiménez, Alvaro Sanabria Referencia : Minerva Endocrinol (Torino). 2022 Jul 13. DOI (Digital Object Identifier) : 10.23736/S2724-6507.22.03813-1 PMID : 35822431 En línea : https://www.minervamedica.it/en/journals/minerva-endocrinology/article.php?cod=R [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001903	AC-2022-067	Archivo digital	Producción Científica	Artículos científicos	Disponible

---

1 (1 - 2 / 2) Por página: 25 50 100 200